Chen J, et al. - Experts conducted a meta-analysis to assess the efficacy and safety of apatinib in patients with advanced gastric cancer (AGC) via statistical analysis data of 1,069 subjects from 13 randomized clinical trials (RCTs). According to the findings, apatinib displayed short-term efficacy vs no-apatinib regimens or placebo, irrespective of its use as first- or second-line chemotherapy or for further treatment in patients with AGC with adverse events of apparently any grade.